A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough

Background: In two phase 3, global clinical trials (COUGH-1 and COUGH-2), the P2X3-receptor antagonist gefapixant significantly reduced objective 24-h cough frequency in participants with refractory or unexplained chronic cough (RCC or UCC) at a dosage of 45 mg twice daily (BID), with an acceptable...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Akio Niimi, Hironori Sagara, Masashi Kikuchi, Ichiro Arano, Asako Sato, Masayoshi Shirakawa, Carmen La Rosa, David Muccino
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2022-10-01
Serija:	Allergology International
Teme:	Antitussive agents Cough Gefapixant Quality of life Safety
Online dostop:	http://www.sciencedirect.com/science/article/pii/S1323893022000478
Oznake:	Označite Brez oznak, prvi označite!